Paragon Associates & Paragon Associates Ii Joint Venture Has Raised By $720,000 Its Citigroup (C) Stake; Last Week SCYNEXIS, Inc. (SCYX) Coverage

December 21, 2017 - By Hazel Jackson

Among 7 analysts covering Scynexis Inc (NASDAQ:SCYX), 6 have Buy rating, 0 Sell and 1 Hold. Therefore 86% are positive. Scynexis Inc had 13 analyst reports since August 20, 2015 according to SRatingsIntel. WBB Securities upgraded the shares of SCYX in report on Tuesday, August 9 to “Buy” rating. The rating was initiated by Brean Capital with “Buy” on Monday, October 3. The firm has “Buy” rating by H.C. Wainwright given on Wednesday, August 16. The stock of SCYNEXIS, Inc. (NASDAQ:SCYX) has “Buy” rating given on Thursday, August 20 by Needham. The firm has “Hold” rating by Needham given on Wednesday, August 9. The firm earned “Buy” rating on Thursday, October 20 by H.C. Wainwright. The stock of SCYNEXIS, Inc. (NASDAQ:SCYX) has “Buy” rating given on Monday, March 28 by Brean Capital. WBB Securities upgraded SCYNEXIS, Inc. (NASDAQ:SCYX) on Friday, October 7 to “Strong Buy” rating. The rating was maintained by RBC Capital Markets on Monday, November 16 with “Outperform”. The firm has “Strong Buy” rating by WBB Securities given on Tuesday, December 29. See SCYNEXIS, Inc. (NASDAQ:SCYX) latest ratings:

24/10/2017 Broker: Guggenheim Rating: Buy New Target: $6 Initiates Coverage On
16/08/2017 Broker: H.C. Wainwright Rating: Buy New Target: $14.0 Maintain
09/08/2017 Broker: Needham Rating: Hold Maintain
07/08/2017 Broker: Roth Capital Rating: Buy New Target: $8.5000 Maintain

Paragon Associates & Paragon Associates Ii Joint Venture increased Citigroup Inc (C) stake by 7.41% reported in 2017Q3 SEC filing. Paragon Associates & Paragon Associates Ii Joint Venture acquired 10,000 shares as Citigroup Inc (C)’s stock rose 1.55%. The Paragon Associates & Paragon Associates Ii Joint Venture holds 145,000 shares with $10.55 million value, up from 135,000 last quarter. Citigroup Inc now has $200.47 billion valuation. The stock increased 1.55% or $1.16 during the last trading session, reaching $75.82. About 13.98M shares traded. Citigroup Inc. (NYSE:C) has risen 35.60% since December 21, 2016 and is uptrending. It has outperformed by 18.90% the S&P500.

SCYNEXIS, Inc., a drug development company, develops and commercializes anti-infectives to address unmet therapeutic needs. The company has market cap of $65.97 million. It is developing its lead product candidate, SCY-078, as a novel oral and intravenous drug for the treatment of various fungal infections, including serious and life-threatening invasive fungal infections. It currently has negative earnings. The firm also develops SCY-078, which is in various Phase I studies for the oral and intravenous formulations, as well as has completed Phase II study as a step-down therapy in patients with invasive candidiasis and vulvovaginal candidiasis.

The stock increased 3.59% or $0.08 during the last trading session, reaching $2.31. About 153,952 shares traded. SCYNEXIS, Inc. (NASDAQ:SCYX) has declined 46.67% since December 21, 2016 and is downtrending. It has underperformed by 63.37% the S&P500.

Investors sentiment increased to 1.09 in 2017 Q3. Its up 0.09, from 1 in 2017Q2. It is positive, as 5 investors sold SCYNEXIS, Inc. shares while 6 reduced holdings. 4 funds opened positions while 8 raised stakes. 8.55 million shares or 7.29% less from 9.22 million shares in 2017Q2 were reported. Vanguard Gru owns 832,987 shares or 0% of their US portfolio. Federated Investors Pa holds 4.21 million shares or 0.03% of its portfolio. Us Bank De holds 0% or 31,500 shares. Virtu Financial Limited Liability Co reported 0% stake. Iguana Healthcare Mngmt Ltd Com has invested 0.34% in SCYNEXIS, Inc. (NASDAQ:SCYX). Royal National Bank & Trust Of Canada holds 0% or 7,304 shares. Northern Tru reported 41,692 shares stake. Art Advisors Lc stated it has 0.01% in SCYNEXIS, Inc. (NASDAQ:SCYX). Commercial Bank Of Ny Mellon stated it has 19,455 shares. Blackrock reported 99,827 shares. Gsa Ptnrs Limited Liability Partnership stated it has 0.03% of its portfolio in SCYNEXIS, Inc. (NASDAQ:SCYX). Moreover, Dimensional Fund Advsr Lp has 0% invested in SCYNEXIS, Inc. (NASDAQ:SCYX) for 109,572 shares. Millennium Management Limited Liability Corp has 0% invested in SCYNEXIS, Inc. (NASDAQ:SCYX) for 40,528 shares. Massachusetts-based Granite Point Capital Lp has invested 0.07% in SCYNEXIS, Inc. (NASDAQ:SCYX). Opus Point Ptnrs Limited Liability Com reported 66,608 shares.

Investors sentiment increased to 1.35 in 2017 Q3. Its up 0.25, from 1.1 in 2017Q2. It increased, as 56 investors sold C shares while 400 reduced holdings. 125 funds opened positions while 492 raised stakes. 2.04 billion shares or 0.42% more from 2.03 billion shares in 2017Q2 were reported. Asset Strategies invested in 0.63% or 15,205 shares. Institute For Wealth Mgmt Ltd has 28,150 shares for 0.67% of their portfolio. Connable Office has 1.3% invested in Citigroup Inc. (NYSE:C). Canada Pension Plan Inv Board reported 5.78M shares. Hollow Brook Wealth Management Ltd reported 1.48% stake. Suffolk Cap Mgmt Ltd Liability Co has invested 2.17% in Citigroup Inc. (NYSE:C). Nepsis Management Incorporated, Minnesota-based fund reported 90,195 shares. Credit Capital Limited Liability Corporation holds 3.05% in Citigroup Inc. (NYSE:C) or 38,000 shares. The Connecticut-based Timber Hill Ltd Liability Corporation has invested 0.16% in Citigroup Inc. (NYSE:C). 818,832 were accumulated by Fiera Cap. Cim Mangement Inc holds 27,458 shares or 0.73% of its portfolio. The Maine-based Hm Payson & has invested 0.01% in Citigroup Inc. (NYSE:C). Ls Investment Advsr Limited Liability Co reported 0.41% in Citigroup Inc. (NYSE:C). Ssi Investment Mgmt reported 0.13% stake. Amundi Pioneer Asset Inc stated it has 1.34% in Citigroup Inc. (NYSE:C).